| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed28726de9f916f355f8adc331e736b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2022-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0482cbe511c279fb476871a8107abef5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7a9f5b7700af7e3422ddd763115ad4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28736b24d38c4218e293343b27e42c5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9248f66f8e70be32ab72653c5dacba68 |
| publicationDate |
2022-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022221650-A1 |
| titleOfInvention |
Therapeutic cd99 antibodies |
| abstract |
The present disclosure relates to an antibody-based molecule that binds CD99. This antibody- based molecule comprises a heavy chain variable region having: (i) a complementarity- determining region 1 (CDR-H1) comprising an amino acid sequence of any one of SEQ ID NOs: 1-3, or a modified amino acid sequence of any one of SEQ ID NOs: 1-3; (ii) a complementarity- determining region 2 (CDR-H2) comprising an amino acid sequence of any one of SEQ ID NOs: 4-10, or a modified amino acid sequence of any one of SEQ ID NOs: 4-10; and/or (iii) a complementarity-determining region 3 (CDR-H3) comprising an amino acid sequence of any one of SEQ ID NOs: 11-14, or a modified amino acid sequence of any one of SEQ ID NO: 11- 14. Also disclosed are isolated polynucleotides encoding the antibody-based molecules, vectors comprising said isolated polynucleotides, as well as pharmaceutical compositions comprising the same and methods of use thereof. |
| priorityDate |
2021-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |